FOXO Technologies
FOXO Technologies, listed on the New York Stock Exchange since September 16, 2022, offers saliva-based epigenetic technology to transform insurance underwriting and sales, alongside advanced epigenetic testing services and bioinformatic tools.
Company Overview
FOXO Technologies is a pioneer in the field of epigenetics, offering cutting-edge technologies and services primarily aimed at transforming how insurance companies underwrite and sell their products. The company was listed on the New York Stock Exchange on September 16, 2022. FOXO Technologies leverages saliva-based epigenetic technology to enhance underwriting processes and drive innovation in longevity risk classification.
Epigenetic Testing Services
FOXO Technologies provides advanced epigenetic testing services designed to support groundbreaking research. Their proprietary Human Methylation Array technology allows researchers to process human samples and examine thousands of CpG sites using state-of-the-art bioinformatics. This array helps in understanding the biological aging process and developing predictive models for various aging outcomes.
Proprietary Technology and IP
FOXO Technologies holds proprietary intellectual property that covers the use of epigenetic biomarkers for longevity risk classification, probe selection, and the application of advanced machine learning and AI techniques. This IP portfolio supports the company's innovations in epigenetic clocks, such as Mortality Predictor EEAA, PhenoAge, and GrimAge, which provide insights into biological aging and healthspan predictions.
Key Collaborations
FOXO Technologies collaborates with several entities to advance its research and product offerings. Notably, they teamed up with the Van Andel Institute and Illumina to develop the Mouse Methylation array, which aids precision-based diagnostics and therapeutic medicine research. Furthermore, the company has a collaboration with DataRobot to integrate AI-driven epigenetic biomarker research aimed at improving human longevity.
Consumer Products and Services
FOXO Technologies has ventured into the consumer market with the direct-to-consumer launch of their Longevity Report (beta). This product leverages the company’s extensive research and technology in epigenetics to provide individuals with insights into their biological aging and healthspan. Additionally, FOXO Technologies offers various bioinformatic software packages to simplify and automate the analysis of complex DNA methylation data, further empowering consumers and researchers alike.